Shamis & Gentile, P.A. is investigating claims on behalf of investors of Bruker Corporation (“Bruker” or the “Company”) (NASDAW: BRKR). Impacted investors are advised to contact the firm now.
The investigation concerns whether Bruker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. The investigation is presently focused on Company statements regarding its financial outlook and demand trends in core markets since 2024.
On July 21, 2025, Bruker announced preliminary results for the second quarter of 2025, disclosing revenue of approximately $795–798 million (flat year-over-year) and a 7% organic decline, citing weak bookings from “soft academic demand” and U.S. biopharma. On this news, Bruker’s stock price fell $3.74 per share, or approximately 10%, to close at $36.82 per share on July 21, 2025, erasing several hundred million dollars in market capitalization.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
